Innovative medicines offer our best hope to effectively manage disease and contain long-term healthcare costs, which is why Amgen prices its medicines responsibly, partners with payers to align on value, and develops patient support programs to help ensure broad access of our novel therapies to appropriate patients. Our high-quality, potentially more affordable biosimilars provide additional treatment options and have the potential to expand access.
Amgen is committed to the responsible pricing of our products according to the value they deliver and aligning with the specific requirements of the health system of each individual country. That’s why we consider the economic and social value of our medicines and the clinical and economic burden of diseases in our approach to pricing in the individual countries in which we operate.
Backed by Amgen’s four decades of biologics expertise, our high-quality biosimilars can potentially offer more affordable, life-altering treatment options that contribute to the sustainability of our healthcare system and allow for greater investment in new medicines for patients.1
Amgen has one of the largest stakes for biosimilars in the industry. As we continue to launch biosimilars over the coming years, we believe that they will bring meaningful cost savings to patients and the healthcare system.For more information, visit our Amgenbiosimilars.com website
Through patient assistance programs, expanded access to investigational therapies, donations, and other programs, we’ve developed support programs for eligible patients around the world as they seek to obtain the medications they need.
References1 IQVIA (2018). The Impact of Biosimilar Competition in Europe. PDF file. Retrieved from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf